Our Partners

We have established numerous strategic collaborations to increase our pipeline of assets, explore new treatment areas, and advance our oncology programs to broaden the patient populations we serve.

Apollomics Partners_chia tai
We have the rights to APL-502 outside mainland China. Chia Tai TianQing Pharmaceutical Group (CTTQ Pharma) has development and commercialization rights in mainland China for APL-502 where it is referred to as TQB2450.
Edison Oncology
We in-licensed from Edison Oncology Holding Corp. exclusive rights to develop and commercialize EO1001 (APL-122) globally, except in mainland China, Hong Kong and Taiwan. 
Apollomics Partners_genor
We have the rights to APL-501 outside mainland China. Genor BioPharma Co., Ltd. has development and commercialization rights in mainland China for APL-501 where it is referred to as GB226.
GlycoMimetics, Inc.
We in-licensed from GlycoMimetics, Inc. exclusive rights to uproleselan (APL-106) and GMI-1687 (APL-108) in mainland China, Hong Kong, Macau and Taiwan.
Nuance Biotech
We in-licensed from Nuance Biotech, Inc. and TYG Oncology Ltd. the rights to TYG100 (APL-810) in mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa.
Apollomics Partners_pearl
We have the rights to APL-101 outside mainland China, Hong Kong and Macau. Beijing Pearl Biotechnology Co., Ltd. has the exclusive rights in mainland China, Hong Kong and Macau for APL-101 where it is referred to as PLB1001.